Gastrointestinal stromal tumor natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
 
Most common site of involvement of GIST is stomach(70%).
==Natural history==
==Natural history==
Common sites of involvement include:
Common sites of involvement include:
Line 13: Line 13:
*Oesophagus
*Oesophagus


GISTs occur not only anywhere along the gastrointestinal tract, but also in the mesentery, omentum and retroperitoneum, which is called  extra-gastrointestinal GISTs 1,4.
GISTs occur not only anywhere along the gastrointestinal tract, but also in the mesentery, omentum and retroperitoneum, which is called  extra-gastrointestinal GISTs. Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs
 
Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs
==Prognosis==
==Prognosis==
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:

Revision as of 15:00, 3 September 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Gastrointestinal stromal tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gastrointestinal stromal tumor from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal stromal tumor natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal stromal tumor natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal stromal tumor natural history

CDC on Gastrointestinal stromal tumor natural history

Gastrointestinal stromal tumor natural history in the news

Blogs on Gastrointestinal stromal tumor natural history

Directions to Hospitals Treating Gastrointestinal stromal tumor

Risk calculators and risk factors for Gastrointestinal stromal tumor natural history

Overview

Most common site of involvement of GIST is stomach(70%).

Natural history

Common sites of involvement include:

  • Stomach: 70%
  • Small intestine: 20-25%
  • Anorectum: 7%
  • Oesophagus

GISTs occur not only anywhere along the gastrointestinal tract, but also in the mesentery, omentum and retroperitoneum, which is called extra-gastrointestinal GISTs. Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs

Prognosis

At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:

  • Mitotic index (mitoses per 50 high-power fields)
  • Tumor size
  • Tumor location[1]

Refrences

  1. "Risk Assessment and Prognosis".


Template:WikiDoc Sources